Physician profile
Lauren Senita
NPI 1083187652
$8,499.42
in general payments reported to CMS, 2019-2025
26 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 97% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $1,491 · 2023: $2,020 · 2024: $2,733 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,428 · Education: $93.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,428.02 |
| Education | $93.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $941.63 | 2021-2025 | Sotyktu |
| Janssen Biotech, INC. | $838.81 | 2022-2024 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $633.66 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $603.60 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Genzyme Corporation | $537.66 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $513.07 | 2024-2025 | |
| Pfizer INC. | $460.36 | 2022-2025 | |
| Journey Medical Corporation | $434.33 | 2022-2025 | |
| Ucb, INC. | $348.72 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $318.96 | 2021-2023 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $317.87 | 2021-2025 | Dupixent |
| Amgen INC. | $307.78 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $294.84 | 2023-2024 | Vtama |
| Lilly USA, LLC | $213.18 | 2021-2025 | Taltz, Ebglyss |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $179.44 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $105.13 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $104.54 | 2022 | |
| Organon LLC | $72.77 | 2025 | Nexplanon, Vtama |
| Arcutis Biotherapeutics, INC. | $61.94 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.93 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $38.99 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $29.78 | 2021 | |
| Paratek Pharmaceuticals, INC. | $28.13 | 2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.87 | 2023 | Jublia, Arazlo |
| Biofrontera INC. | $19.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Senita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.